Literature DB >> 30045982

Sera from Individuals with Narrowly Focused Influenza Virus Antibodies Rapidly Select Viral Escape Mutations In Ovo.

Amy K F Davis1, Kevin McCormick1, Megan E Gumina1, Joshua G Petrie2, Emily T Martin2, Katherine S Xue3,4, Jesse D Bloom3,4, Arnold S Monto2, Frederic D Bushman1, Scott E Hensley5.   

Abstract

Influenza viruses use distinct antibody escape mechanisms depending on the overall complexity of the antibody response that is encountered. When grown in the presence of a hemagglutinin (HA) monoclonal antibody, influenza viruses typically acquire a single HA mutation that reduces the binding of that specific monoclonal antibody. In contrast, when confronted with mixtures of HA monoclonal antibodies or polyclonal sera that have antibodies that bind several HA epitopes, influenza viruses acquire mutations that increase HA binding to host cells. Recent data from our laboratory and others suggest that some humans possess antibodies that are narrowly focused on HA epitopes that were present in influenza virus strains that they were likely exposed to in childhood. Here, we completed a series of experiments to determine if humans with narrowly focused HA antibody responses are able to select for influenza virus antigenic escape variants in ovo We identified three human donors that possessed HA antibody responses that were heavily focused on a single HA antigenic site. Sera from all three of these donors selected single HA escape mutations during in ovo passage experiments, similar to what has been previously reported for single monoclonal antibodies. These single HA mutations directly reduced binding of serum antibodies used for selection. We propose that new antigenic variants of influenza viruses might originate in individuals who produce antibodies that are narrowly focused on HA epitopes that were present in viral strains that they encountered in childhood.IMPORTANCE Influenza vaccine strains must be updated frequently since circulating viral strains continuously change in antigenically important epitopes. Our previous studies have demonstrated that some individuals possess antibody responses that are narrowly focused on epitopes that were present in viral strains that they encountered during childhood. Here, we show that influenza viruses rapidly escape this type of polyclonal antibody response when grown in ovo by acquiring single mutations that directly prevent antibody binding. These studies improve our understanding of how influenza viruses evolve when confronted with narrowly focused polyclonal human antibodies.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  antibody; influenza; mutation

Mesh:

Substances:

Year:  2018        PMID: 30045982      PMCID: PMC6146816          DOI: 10.1128/JVI.00859-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Diverse antigenic site targeting of influenza hemagglutinin in the murine antibody recall response to A(H1N1)pdm09 virus.

Authors:  Jason R Wilson; Zhu Guo; Wen-Pin Tzeng; Rebecca J Garten; Xu Xiyan; Elisabeth G Blanchard; Kristy Blanchfield; James Stevens; Jacqueline M Katz; Ian A York
Journal:  Virology       Date:  2015-08-27       Impact factor: 3.616

2.  Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands.

Authors:  R Bodewes; G de Mutsert; F R M van der Klis; M Ventresca; S Wilks; D J Smith; M Koopmans; R A M Fouchier; A D M E Osterhaus; G F Rimmelzwaan
Journal:  Clin Vaccine Immunol       Date:  2011-01-05

Review 3.  Viva la revolución: rethinking influenza a virus antigenic drift.

Authors:  Jonathan W Yewdell
Journal:  Curr Opin Virol       Date:  2011-09       Impact factor: 7.090

4.  Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift.

Authors:  Scott E Hensley; Suman R Das; Adam L Bailey; Loren M Schmidt; Heather D Hickman; Akila Jayaraman; Karthik Viswanathan; Rahul Raman; Ram Sasisekharan; Jack R Bennink; Jonathan W Yewdell
Journal:  Science       Date:  2009-10-30       Impact factor: 47.728

5.  Focused antibody response to influenza linked to antigenic drift.

Authors:  Kuan-Ying A Huang; Pramila Rijal; Lisa Schimanski; Timothy J Powell; Tzou-Yien Lin; John W McCauley; Rodney S Daniels; Alain R Townsend
Journal:  J Clin Invest       Date:  2015-05-26       Impact factor: 14.808

6.  Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection.

Authors:  Jens Wrammert; Dimitrios Koutsonanos; Gui-Mei Li; Srilatha Edupuganti; Jianhua Sui; Michael Morrissey; Megan McCausland; Ioanna Skountzou; Mady Hornig; W Ian Lipkin; Aneesh Mehta; Behzad Razavi; Carlos Del Rio; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Zahida Ali; Kaval Kaur; Sarah Andrews; Rama Rao Amara; Youliang Wang; Suman Ranjan Das; Christopher David O'Donnell; Jon W Yewdell; Kanta Subbarao; Wayne A Marasco; Mark J Mulligan; Richard Compans; Rafi Ahmed; Patrick C Wilson
Journal:  J Exp Med       Date:  2011-01-10       Impact factor: 14.307

7.  Parallel evolution of influenza across multiple spatiotemporal scales.

Authors:  Katherine S Xue; Terry Stevens-Ayers; Angela P Campbell; Janet A Englund; Steven A Pergam; Michael Boeckh; Jesse D Bloom
Journal:  Elife       Date:  2017-06-27       Impact factor: 8.140

8.  Complete mapping of viral escape from neutralizing antibodies.

Authors:  Michael B Doud; Scott E Hensley; Jesse D Bloom
Journal:  PLoS Pathog       Date:  2017-03-13       Impact factor: 6.823

9.  Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody.

Authors:  Donald D Raymond; Goran Bajic; Jack Ferdman; Pirada Suphaphiphat; Ethan C Settembre; M Anthony Moody; Aaron G Schmidt; Stephen C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-18       Impact factor: 11.205

10.  Antibodies Against the Current Influenza A(H1N1) Vaccine Strain Do Not Protect Some Individuals From Infection With Contemporary Circulating Influenza A(H1N1) Virus Strains.

Authors:  Joshua G Petrie; Kaela Parkhouse; Suzanne E Ohmit; Ryan E Malosh; Arnold S Monto; Scott E Hensley
Journal:  J Infect Dis       Date:  2016-10-07       Impact factor: 7.759

View more
  10 in total

1.  Sera from Individuals with Narrowly Focused Influenza Virus Antibodies Rapidly Select Viral Escape Mutations In Ovo.

Authors:  Amy K F Davis; Kevin McCormick; Megan E Gumina; Joshua G Petrie; Emily T Martin; Katherine S Xue; Jesse D Bloom; Arnold S Monto; Frederic D Bushman; Scott E Hensley
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

2.  Earliest infections predict the age distribution of seasonal influenza A cases.

Authors:  Philip Arevalo; Huong Q McLean; Edward A Belongia; Sarah Cobey
Journal:  Elife       Date:  2020-07-07       Impact factor: 8.140

3.  Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin.

Authors:  Juhye M Lee; Rachel Eguia; Seth J Zost; Saket Choudhary; Patrick C Wilson; Trevor Bedford; Terry Stevens-Ayers; Michael Boeckh; Aeron C Hurt; Seema S Lakdawala; Scott E Hensley; Jesse D Bloom
Journal:  Elife       Date:  2019-08-27       Impact factor: 8.140

4.  Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.

Authors:  Alexandra C Walls; Brooke Fiala; Alexandra Schäfer; Samuel Wrenn; Minh N Pham; Michael Murphy; Longping V Tse; Laila Shehata; Megan A O'Connor; Chengbo Chen; Mary Jane Navarro; Marcos C Miranda; Deleah Pettie; Rashmi Ravichandran; John C Kraft; Cassandra Ogohara; Anne Palser; Sara Chalk; E-Chiang Lee; Kathryn Guerriero; Elizabeth Kepl; Cameron M Chow; Claire Sydeman; Edgar A Hodge; Brieann Brown; Jim T Fuller; Kenneth H Dinnon; Lisa E Gralinski; Sarah R Leist; Kendra L Gully; Thomas B Lewis; Miklos Guttman; Helen Y Chu; Kelly K Lee; Deborah H Fuller; Ralph S Baric; Paul Kellam; Lauren Carter; Marion Pepper; Timothy P Sheahan; David Veesler; Neil P King
Journal:  Cell       Date:  2020-10-31       Impact factor: 41.582

5.  Serotypic evolution of measles virus is constrained by multiple co-dominant B cell epitopes on its surface glycoproteins.

Authors:  Miguel Ángel Muñoz-Alía; Rebecca A Nace; Lianwen Zhang; Stephen J Russell
Journal:  Cell Rep Med       Date:  2021-03-30

Review 6.  Antigenic drift: Understanding COVID-19.

Authors:  Jonathan W Yewdell
Journal:  Immunity       Date:  2021-12-14       Impact factor: 31.745

7.  Low quality antibody responses in critically ill patients hospitalized with pandemic influenza A(H1N1)pdm09 virus infection.

Authors:  Xiuhua Lu; Zhu Guo; Zhu-Nan Li; Crystal Holiday; Feng Liu; Stacie Jefferson; F Liaini Gross; Wen-Ping Tzeng; Anand Kumar; Ian A York; Timothy M Uyeki; Terrence Tumpey; James Stevens; Min Z Levine
Journal:  Sci Rep       Date:  2022-09-02       Impact factor: 4.996

8.  Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2.

Authors:  Alexandra C Walls; Brooke Fiala; Alexandra Schäfer; Samuel Wrenn; Minh N Pham; Michael Murphy; Longping V Tse; Laila Shehata; Megan A O'Connor; Chengbo Chen; Mary Jane Navarro; Marcos C Miranda; Deleah Pettie; Rashmi Ravichandran; John C Kraft; Cassandra Ogohara; Anne Palser; Sara Chalk; E-Chiang Lee; Elizabeth Kepl; Cameron M Chow; Claire Sydeman; Edgar A Hodge; Brieann Brown; Jim T Fuller; Kenneth H Dinnon; Lisa E Gralinski; Sarah R Leist; Kendra L Gully; Thomas B Lewis; Miklos Guttman; Helen Y Chu; Kelly K Lee; Deborah H Fuller; Ralph S Baric; Paul Kellam; Lauren Carter; Marion Pepper; Timothy P Sheahan; David Veesler; Neil P King
Journal:  bioRxiv       Date:  2020-08-12

9.  Slowing Influenza Virus Evolution: A Role for Multiple Synergistic Antiviral Specificities in Vaccination Strategies.

Authors:  Bernard A P Lafont; Jack R Bennink
Journal:  Viral Immunol       Date:  2020-04       Impact factor: 2.257

10.  Impaired Vaccine-Induced Antibody Response Against Clade 6B H1N1 Viruses in Individuals Before Viral Emergence.

Authors:  Kuan-Ying A Huang; Yhu-Chering Huang; Cheng-Hsun Chiu; Kuo-Chien Tsao; Tzou-Yien Lin
Journal:  Open Forum Infect Dis       Date:  2020-01-11       Impact factor: 3.835

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.